Company profile for Tiefenbacher Group

PharmaCompass

We are the TIEFENBACHER GROUP, Health Pioneers since 1963.

Related CompaniesRelated Companies

About

Founded in 1963 as the world’s first exclusive agency for APIs, the Tiefenbacher Group has evolved into a leading healthcare company offering innovative solutions across the entire pharmaceutical value chain. Tiefenbacher distributes raw materials and excels in the development, manufacture and registration of FDFs, including tablets, capsules, powders, drops, patches and medical devices. Tiefenbacher offers integrated services like pharmaceutical distribution, supply chain management, contract manufacturing, regulatory consulting and market access support. It aims to provide affordable, high-quality healthcare solutions worldwide.

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Germany
Address
Address
Van-der-Smissen-Strasse 1, 22767 Hamburg
Telephone
Telephone
+49 404418090
youtube
YouTube
Twitter
Twitter
Contact Info
Others

Events

Webinars & Exhibitions

Default Event

CPhI North America

Not Confirmed

envelop Contact Supplier

CPhI North America

Post an Enquiry

Meeting

Digital content read-more

Explore the latest content creation from this company

CORPORATE CONTENT #SupplierSpotlight

    https://www.pharmacompass.com/pdf/party/content/tiefenbacher-group-party-content-21386.pdf

    https://www.pharmacompass.com/pdf/party/content/tiefenbacher-group-party-content-26459.pdf

    https://www.pharmacompass.com/pdf/party/content/tiefenbacher-group-party-content-7484.pdf

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/lindus-health-and-tiefenbacher-group-launching-clinical-trial-to-advance-mecfs-research-and-treatment-302393805.html

PR NEWSWIRE
06 Mar 2025

https://tiefenbacher-pharmaceuticals.com/2024/05/02/tiefenbacher-group-renovation-of-headquarters-in-hamburg/

PRESS RELEASE
02 May 2024

https://tiefenbacher-pharmaceuticals.com/2024/04/09/tiefenbacher-first-to-market-launch-rivaroxaban/

PRESS RELEASE
09 Apr 2024

https://tiefenbacher-pharmaceuticals.com/2024/04/08/tiefenbacher-group-welcomes-new-coo-sandip-tarate/

PRESS RELEASE
08 Apr 2024

https://tiefenbacher-pharmaceuticals.com/2024/03/19/tiefenbacher-group-awarded-ecovadis-silver-medal/

PRESS RELEASE
19 Mar 2024

https://tiefenbacher-pharmaceuticals.com/2024/02/29/tiefenbacher-group-on-awareness-for-rare-disease-day/

PRESS RELEASE
29 Feb 2024

Drugs in Development

read-more
read-more

Details:

Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.


Lead Product(s): Rivaroxaban

Therapeutic Area: Hematology Brand Name: Xarelto-Generic

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 04, 2024

Tiefenbacher Compnay Banner

01

Lead Product(s) : Rivaroxaban

Therapeutic Area : Hematology

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.

Product Name : Xarelto-Generic

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

September 04, 2024

Tiefenbacher Compnay Banner

Details:

Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.


Lead Product(s): Rivaroxaban

Therapeutic Area: Hematology Brand Name: Xarelto-Generic

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 16, 2023

Tiefenbacher Compnay Banner

02

Lead Product(s) : Rivaroxaban

Therapeutic Area : Hematology

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.

Product Name : Xarelto-Generic

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

November 16, 2023

Tiefenbacher Compnay Banner

Details:

Aubagio-Generic (teriflunomide) is a USFDA approved pyrimidine synthesis inhibitor which is indicated for the treatment of patients with relapsing forms of multiple sclerosis.


Lead Product(s): Teriflunomide

Therapeutic Area: Neurology Brand Name: Aubagio-Generic

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 27, 2023

Tiefenbacher Compnay Banner

03

Lead Product(s) : Teriflunomide

Therapeutic Area : Neurology

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Aubagio-Generic (teriflunomide) is a USFDA approved pyrimidine synthesis inhibitor which is indicated for the treatment of patients with relapsing forms of multiple sclerosis.

Product Name : Aubagio-Generic

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

September 27, 2023

Tiefenbacher Compnay Banner

Details:

Bilastine Tiefenbacher (Bilastine) is a histamine H1 receptor inverse agonist, small molecule drug candidate which is indicated for the treatment of allergic rhino-conjunctivitis & urticaria.


Lead Product(s): Bilastine

Therapeutic Area: Immunology Brand Name: Bilastine Tiefenbacher

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 14, 2023

Tiefenbacher Compnay Banner

04

Lead Product(s) : Bilastine

Therapeutic Area : Immunology

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Bilastine Tiefenbacher (Bilastine) is a histamine H1 receptor inverse agonist, small molecule drug candidate which is indicated for the treatment of allergic rhino-conjunctivitis & urticaria.

Product Name : Bilastine Tiefenbacher

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

March 14, 2023

Tiefenbacher Compnay Banner

Details:

Abiraterone and the combination product Abiraterone/Prednisolone are used to treat men with prostate cancer. The 500 mg (mono product) and 500 mg + 5 mg (combination product) tablets will be marketed in Europe by our partners.


Lead Product(s): Abiraterone Acetate,Prednisolone

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Approved FDFProduct Type: Hormone

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 17, 2022

Tiefenbacher Compnay Banner

05

Lead Product(s) : Abiraterone Acetate,Prednisolone

Therapeutic Area : Oncology

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Abiraterone and the combination product Abiraterone/Prednisolone are used to treat men with prostate cancer. The 500 mg (mono product) and 500 mg + 5 mg (combination product) tablets will be marketed in Europe by our partners.

Product Name : Undisclosed

Product Type : Hormone

Upfront Cash : Inapplicable

November 17, 2022

Tiefenbacher Compnay Banner

Details:

Apixaban Tiefenbacher (apixaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.


Lead Product(s): Apixaban

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Apixaban Tiefenbacher

Study Phase: Approved FDFProduct Type: HPAPI

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 20, 2022

Tiefenbacher Compnay Banner

06

Lead Product(s) : Apixaban

Therapeutic Area : Cardiology/Vascular Diseases

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Apixaban Tiefenbacher (apixaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

Product Name : Apixaban Tiefenbacher

Product Type : HPAPI

Upfront Cash : Inapplicable

October 20, 2022

Tiefenbacher Compnay Banner

Details:

Vildagliptin/Metformin generic version launched in Africa market, the drug ais a diabetes medicine that are used to control the blood glucose (sugar) in adults with type 2 diabetes, by inhibiting DPP-4.


Lead Product(s): Vildagliptin,Metformin

Therapeutic Area: Endocrinology Brand Name: Vildagliptin-Metformin-Generic

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 09, 2022

Tiefenbacher Compnay Banner

07

Lead Product(s) : Vildagliptin,Metformin

Therapeutic Area : Endocrinology

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Vildagliptin/Metformin generic version launched in Africa market, the drug ais a diabetes medicine that are used to control the blood glucose (sugar) in adults with type 2 diabetes, by inhibiting DPP-4.

Product Name : Vildagliptin-Metformin-Generic

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

August 09, 2022

Tiefenbacher Compnay Banner

Details:

Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.


Lead Product(s): Rivaroxaban

Therapeutic Area: Hematology Brand Name: Xarelto-Generic

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 15, 2022

Tiefenbacher Compnay Banner

08

Lead Product(s) : Rivaroxaban

Therapeutic Area : Hematology

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.

Product Name : Xarelto-Generic

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

July 15, 2022

Tiefenbacher Compnay Banner

Details:

Lacosamide is a functionalized amino acid that has activity in the maximal electroshock seizure test, and is indicated for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain.


Lead Product(s): Lacosamide

Therapeutic Area: Neurology Brand Name: Lacosamide-Generic

Study Phase: Approved FDFProduct Type: Controlled Substance

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 22, 2022

Tiefenbacher Compnay Banner

09

Lead Product(s) : Lacosamide

Therapeutic Area : Neurology

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Lacosamide is a functionalized amino acid that has activity in the maximal electroshock seizure test, and is indicated for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain.

Product Name : Lacosamide-Generic

Product Type : Controlled Substance

Upfront Cash : Inapplicable

March 22, 2022

Tiefenbacher Compnay Banner

Details:

Otezla-Generic (apremilast) is an inhibitor of phosphodiesterase 4 (PDE4). It is indicated for the treatment of adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, and oral ulcers.


Lead Product(s): Apremilast

Therapeutic Area: Dermatology Brand Name: Otezla-Generic

Study Phase: Approved FDFProduct Type: HPAPI

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 12, 2022

Tiefenbacher Compnay Banner

10

Lead Product(s) : Apremilast

Therapeutic Area : Dermatology

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Otezla-Generic (apremilast) is an inhibitor of phosphodiesterase 4 (PDE4). It is indicated for the treatment of adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, and oral ulcers.

Product Name : Otezla-Generic

Product Type : HPAPI

Upfront Cash : Inapplicable

January 12, 2022

Tiefenbacher Compnay Banner
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Inspections and registrations

Check the inspections & registration from this company

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty